title: [THE DYNAMICS OF IMMUNOLOGICAL RESULTS OF PATIENTS WITH T-CELL SKIN LYMPHOMAS AND PSORIASIS BY THE THERAPY OF ACTIVATION MECHANISMS SANOGENESIS METHODS].
abstract: The therapy T-cell skin lymphoma and psoriasis by the application of activation mechanisms sanogenesis methods, such as: original--a treatment plasmapheresis, a standard heparin infusion; used for the first time--wobenzym; solutions of acid acetic food and sodium bicarbonate; known--the basic sanitations of concomitant diseases, photopheresis caused remissions in 79.6% patients with different stages T-cell skin lymphoma (observed over an 8-year span), and in 67% of patients with psoriasis (observed over an 6-year span). Depuration reactions (phagocytosis, pinocytosis, toxin neutralization) has been activated by detoxication of treatment plasmapheresis and heparin infusions. The topical therapy with wobenzym, solutions of acid acetic food and sodium bicarbonate renewed natural immune barrier of skin. Basic therapy of concomitant diseases enhanced of patient state of health and mobilized compensatory resources. Photopheresis initiated autoimmunization processes by malignant CD4+ lymphocytes. When remission was achieved, the parameters of cellular and humoral immunity returned to normal levels, or the parameters made worse in the absence of remission.
authors.forename: D M
authors.initials: DM
authors.lastname: Kurgan
authors.forename: M V
authors.initials: MV
authors.lastname: Kokoruz
authors.forename: M G
authors.initials: MG
authors.lastname: Kurgan
authors.forename: V L
authors.initials: VL
authors.lastname: Novak
mesh_terms: D019342:Acetic Acid / Q000627:therapeutic use; D000328:Adult; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D004338:Drug Combinations; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006493:Heparin / Q000627:therapeutic use*; D006801:Humans; D006867:Hydrolases / Q000627:therapeutic use*; D056724:Immunity, Humoral / Q000187:drug effects; D007113:Immunity, Innate / Q000187:drug effects; D007136:Immunoglobulins / Q000096:biosynthesis; D007155:Immunologic Factors / Q000627:therapeutic use; D016410:Lymphoma, T-Cell, Cutaneous / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010587:Phagocytosis / Q000187:drug effects / Q000276:immunology; D017893:Photopheresis; D010873:Pinocytosis / Q000187:drug effects / Q000276:immunology; D010956:Plasmapheresis; D011565:Psoriasis / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D012074:Remission Induction; D012431:Rutin / Q000627:therapeutic use*; D012867:Skin / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D017693:Sodium Bicarbonate / Q000627:therapeutic use
chemical_list: D004338:Drug Combinations; D005343:Fibrinolytic Agents; D007136:Immunoglobulins; D007155:Immunologic Factors; D012431:Rutin; C023295:Wobenzym; D017693:Sodium Bicarbonate; D006493:Heparin; D006867:Hydrolases; D019342:Acetic Acid